Sleep Apnea and Cardiovascular Disease

Area of Science:

• Cardiology
• Sleep Medicine
• Internal Medicine

Background:

• Obstructive sleep apnea (OSA) is linked to coronary and cerebral vascular diseases.
• Mechanisms include sympathetic overactivity, oxidative stress, inflammation, hypertension, and impaired glucose metabolism.
• Observational studies suggest positive airway pressure (PAP) therapy reduces cardiovascular risk.

Purpose of the Study:

• To review recent clinical trials on the impact of OSA treatment on major cardiovascular disease outcomes.
• To evaluate the effectiveness of PAP therapy in managing cardiovascular risks associated with OSA.

Main Methods:

• Review of multicenter randomized clinical trials evaluating PAP treatment for OSA.
• Analysis of cardiovascular disease events, blood pressure, and glucose metabolism as outcomes.

Main Results:

• PAP therapy shows a modest reduction in blood pressure.
• Improvements in type 2 diabetes mellitus are generally not observed, but prediabetes may benefit.
• Recent trials failed to show a reduction in cardiovascular events, possibly due to non-sleepy study populations.

Conclusions:

• PAP treatment for OSA can lower blood pressure and potentially improve glucose metabolism.
• Current evidence does not support a reduction in cardiovascular risk for minimally symptomatic OSA patients.
• Sleepiness may be a key factor in OSA's cardiovascular impact.